Interleukin-1 and neuronal injury

Nature Reviews Immunology

Volumn 5, Issue 8, 2005, Pages 629-640

  Allan, Stuart M ^a   Tyrrell, Pippa J ^b   Rothwell, Nancy J ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b HOPE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; ALPHA CHEMOKINE; C REACTIVE PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 6; N METHYL DEXTRO ASPARTIC ACID; RECOMBINANT INTERLEUKIN 1; RECOMBINANT PROTEIN;

ASTROCYTE; BRAIN BLOOD FLOW; BRAIN INJURY; CLINICAL TRIAL; CYTOKINE PRODUCTION; DEGENERATIVE DISEASE; DISEASE SEVERITY; DNA POLYMORPHISM; DRUG BRAIN LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; EPILEPSY; GLIA CELL; HUMAN; ISCHEMIA; NERVE CELL; NONHUMAN; OLIGODENDROGLIA; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; STROKE; SUBARACHNOID HEMORRHAGE; TRANSCRIPTION REGULATION; TRANSLATION REGULATION;

ANIMALS; CENTRAL NERVOUS SYSTEM; HUMANS; INTERLEUKIN-1; NEURODEGENERATIVE DISEASES; NEURONS;

EID: 23444441962     PISSN: 14741733     EISSN: None     Source Type: Journal    
DOI: 10.1038/nri1664     Document Type: Review

References (111)

1. Huising, M. O., Stet, R. J., Savelkoul, H. F. & Verburg-van Kemenade, B. M. The molecular evolution of the interleukin-1 family of cytokines; IL-18 in teleost fish. Dev. Comp. Immunol. 28, 395-413 (2004).
2. March, C. J. et al. Cloning, sequence and expression of two distinct human interleukin-1 complementary DNAs. Nature 315, 641-647 (1985).
3. Thornberry, N. A. et al. A novel heterodimeric cysteine protease is required for interleukin-1β processing in monocytes. Nature 356, 768-774 (1992). A key paper that identified the enzyme that is responsible for cleavage of inactive pro-IL-1β to the mature biologically active protein.
4. Sims, J. E. et al. cDNA expression cloning of the IL-1 receptor, a member of the immunoglobulin superfamily. Science 241, 585-589 (1988).
5. Korherr, C., Hofmeister, R., Wesche, H. & Falk, W. A critical role for interleukin-1 receptor accessory protein in interleukin-1 signaling. Eur. J. Immunol. 27, 262-267 (1997). An important paper that shows that recruitment of an accessory protein to the IL-1-IL-1R1 complex is essential for signal transduction to take place.
6. Subramaniam, S., Stansberg, C. & Cunningham, C. The interleukin 1 receptor family. Dev. Comp. Immunol. 28, 415-428 (2004).
7. Hannum, C. H. et al. Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor. Nature 343, 336-340 (1990).
8. Malyak, M., Smith, M. F. Jr, Abel, A. A., Hance, K. R. & Arend, W. P. The differential production of three forms of IL-1 receptor antagonist by human neutrophils and monocytes. J. Immunol. 161, 2004-2010 (1998).
9. Dinarello, C. A. et al. Overview of interleukin-18: more than an interferon-γ inducing factor. J. Leukoc. Biol. 63, 658-664 (1998).
10. Dunne, A. & O'Neill, L. A. The interleukin-1 receptor/Toll-like receptor superfamily: signal transduction during inflammation and host defense. Sci. STKE [online] 2003, RE3 (2003). A valuable updated review of the receptors of the IL-1-receptor and TLR family, and their signalling pathways.
11. Sims, J. E. et al. A new nomenclature for IL-1-family genes. Trends Immunol. 22, 536-537 (2001).
12. Sims, J. E. IL-1 and IL-18 receptors, and their extended family. Curr. Opin. Immunol. 14, 117-122 (2002).
13. Vitkovic, L., Bockaert, J. & Jacque, C. 'Inflammatory' cytokines: neuromodulators in normal brain? J. Neurochem. 74, 457-471 (2000).
14. Watkins, L. R., Hansen, M. K., Nguyen, K. T., Lee, J. E. & Maier, S. F. Dynamic regulation of the proinflammatory cytokine, interleukin-1β: molecular biology for non-molecular biologists. Life Sci. 65, 449-481 (1999).
15. Hsu, H. Y. & Wen, M. H. Lipopolysaccharide-mediated reactive oxygen species and signal transduction in the regulation of interleukin-1 gene expression. J. Biol. Chem. 277, 22131-22139 (2002).
16. Perregaux, D. G., Bhavsar, K., Contillo, L., Shi, J. & Gabel, C. A. Antimicrobial peptides initiate IL-1β posttranslational processing: a novel role beyond innate immunity. J. Immunol. 168, 3024-3032 (2002).
17. Eriksson, C., Tehranian, R., Iverfeldt, K., Winblad, B. & Schultzberg, M. Increased expression of mRNA encoding interleukin-1β and caspase-1, and the secreted isoform of interleukin-1 receptor antagonist in the rat brain following systemic kainic acid administration. J. Neurosci. Res. 60, 266-279 (2000).
18. Liu, L., Li, Y, Van Eldik, L. J., Griffin, W. S. & Barger, S. W. S100B-induced microglial and neuronal IL-1 expression is mediated by cell type-specific transcription factors. J. Neurochem. 92, 546-553 (2005).
19. Relton, J. K. et al. Lipocortin-1 is an endogenous inhibitor of ischemic damage in the rat brain. J. Exp. Med. 174, 305-310 (1991).
20. Kern, J. A., Warnock, L. J. & McCafferty, J. D. The 3′ untranslated region of IL-1β regulates protein production. J. Immunol. 158, 1187-1193 (1997).
21. Hazuda, D. J., Strickler, J., Kueppers, F., Simon, P. L. & Young, P. R. Processing of precursor interleukin 1β and inflammatory disease. J. Biol. Chem. 265, 6318-6322 (1990).
22. Perregaux, D. & Gabel, C. A. Interleukin-1β maturation and release in response to ATP and nigericin. Evidence that potassium depletion mediated by these agents is a necessary and common feature of their activity. J. Biol. Chem. 269, 15195-15203 (1994).
23. Le Feuvre, R. A., Brough, D., Iwakura, Y., Takeda, K. & Rothwell, N. J. Priming of macrophages with lipopolysaccharide potentiates P2X7-mediated cell death via a caspase-1-dependent mechanism, independently of cytokine production. J. Biol. Chem. 277, 3210-3218 (2002).
24. 2+ entry differentially contribute to the release of IL-1β and IL-1α from murine macrophages. J. Immunol. 170, 3029-3036 (2003).
25. Andrei, C. et al. Phospholipases C and A2 control lysosome-mediated IL-1β secretion: implications for inflammatory processes. Proc. Natl Acad. Sci. USA 101, 9745-9750 (2004).
26. Walev, I., Reske, K., Palmer, M., Valeva, A. & Bhakdi, S. Potassium-inhibited processing of IL-1β in human monocytes. EMBO J. 14, 1607-1614 (1995).
27. Ferrari, D. et al. P2Z purinoreceptor ligation induces activation of caspases with distinct roles in apoptotic and necrotic alterations of cell death. FEBS Lett. 447, 71-75 (1999).
28. Elssner, A., Duncan, M., Gavrilin, M. & Wewers, M. D. A novel P2X7 receptor activator, the human cathelicidin-derived peptide LL37, induces IL-1β processing and release. J. Immunol. 172, 4987-4994 (2004).
29. Perregaux, D. G. et al. Identification and characterization of a novel class of interleukin-1 post-translational processing inhibitors. J. Pharmacol. Exp. Ther. 299, 187-197 (2001).
30. Laliberte, R. E. et al. Glutathione S-transferase ω 1-1 is a target of cytokine release inhibitory drugs and may be responsible for their effect on interleukin-1β posttranslational processing. J. Biol. Chem. 278, 16567-16578 (2003).
31. Li, Y. J. et al. Glutathione S-transferase ω-1 modifies age-at-onset of Alzheimer disease and Parkinson disease. Hum. Mol. Genet. 12, 3259-3267 (2003).
32. Schneider, H. et al. A neuromodulatory role of interleukin-1β in the hippocampus. Proc. Natl Acad. Sci. USA 95, 7778-7783 (1998).
33. Kelley, K. W. et al. Cytokine-induced sickness behavior. Brain Behav. Immun. 17, S112-S118 (2003).
34. Berkenbosch, F., van Oers, J., del Rey, A., Tilders, F. & Besedovsky, H. Corticotropin-releasing factor-producing neurons in the rat activated by interleukin-1. Science 238, 524-526 (1987).
35. Boutin, H., Kimber, I., Rothwell, N. J. & Pinteaux, E. The expanding interleukin-1 family and its receptors: do alternative IL-1 receptor/signaling pathways exist in the brain? Mol. Neurobiol. 27, 239-248 (2003).
36. Debets, R. et al. Two novel IL-1 family members, IL-1δ and IL-1ε, function as an antagonist and agonist of NF-κB activation through the orphan IL-1 receptor-related protein 2. J. Immunol. 167, 1440-1446 (2001).
37. Lovenberg, T. W. et al. Cloning of a cDNA encoding a novel interleukin-1 receptor related protein (IL1R-rp2). J. Neuroimmunol. 70, 113-122 (1996).
38. Berglof, E. et al. IL-1Rrp2 expression and IL-1F9 (IL-1H1) actions in brain cells. J. Neuroimmunol. 139, 36-43 (2003).
39. Wang, P. et al. The interleukin-1-related cytokine IL-1F8 is expressed in glial cells, but fails to induce IL-1β signalling responses. Cytokine 29, 245-250 (2005).
40. Ching, S., He, L., Lai, W. & Quan, N. IL-1 type I receptor plays a key role in mediating the recruitment of leukocytes into the central nervous system. Brain Behav. Immun. 19, 127-137 (2005).
41. Loddick, S. A. et al. Endogenous interleukin-1 receptor antagonist is neuroprotective. Biochem. Biophys. Res. Commun. 234, 211-215 (1997).
42. Carvey, P. M. et al. Intra-parenchymal injection of tumor necrosis factor-α and interleukin 1-β produces dopamine neuron loss in the rat. J. Neural Transm. 112, 601-612 (2005). One of the few papers to show direct neurotoxic effects of IL-1.
43. Lawrence, C. B., Allan, S. M. & Rothwell, N. J. Interleukin-1β and the interleukin-1 receptor antagonist act in the striatum to modify excitotoxic brain damage in the rat. Eur. J. Neurosci. 10, 1188-1195 (1998).
44. Chao, C. C., Hu, S., Ehrlich, L. & Peterson, P. K. Interleukin-1 and tumor necrosis factor-α synergistically mediate neurotoxicity: involvement of nitric oxide and of N-methyl-D-aspartate receptors. Brain. Behav. Immun. 9, 355-365 (1995).
45. Hu, S., Peterson, P. K. & Chao, C. C. Cytokine-mediated neuronal apoptosis. Neurochem. Int. 30, 427-431 (1997).
46. Downen, M., Amaral, T. D., Hua, L. L., Zhao, M. L. & Lee, S. C. Neuronal death in cytokine-activated primary human brain cell culture: role of tumor necrosis factor-α. Glia 28, 114-127 (1999).
47. Yamasaki, Y. et al. Interleukin-1 as a pathogenetic mediator of ischemic brain damage in rats. Stroke 26, 676-681 (1995). The first study to show that administration of exogenous IL-1 can exacerbate experimental neuronal injury.
48. Relton, J. K. & Rothwell, N. J. Interleukin-1 receptor antagonist inhibits ischaemic and excitotoxic neuronal damage in the rat. Brain Res. Bull. 29, 243-246 (1992). The first paper to report the neuroprotective effects of IL-1RA in neuronal injury.
49. Rothwell, N. Interleukin-1 and neuronal injury: mechanisms, modification, and therapeutic potential. Brain Behav. Immun. 17, 152-157 (2003).
50. Vezzani, A. et al. Powerful anticonvulsant action of IL-1 receptor antagonist on intracerebral injection and astrocytic overexpression in mice. Proc. Natl Acad. Sci. USA 97, 11534-11539 (2000).
51. Lin, M. T., Kao, T. Y., Jin, Y. T. & Chen, C. F. Interleukin-1 receptor antagonist attenuates the heat stroke-induced neuronal damage by reducing the cerebral ischemia in rats. Brain Res. Bull. 37, 595-598 (1995).
52. Loscher, C. E., Mills, K. H. & Lynch, M. A. Interleukin-1 receptor antagonist exerts agonist activity in the hippocampus independent of the interleukin-1 type I receptor. J. Neuroimmunol. 137, 117-124 (2003).
53. Hara, H. et al. Inhibition of interleukin 1β converting enzyme family proteases reduces ischemic and excitotoxic neuronal damage. Proc. Natl Acad. Sci. USA 94, 2007-2012 (1997). The first paper to show that inhibition of the enzyme responsible for production of the mature, active IL-1β protein provides neuroprotection.
54. Boutin, H. et al. Role of IL-1α and IL-1β in ischemic brain damage. J. Neurosci. 21, 5528-5534 (2001).
55. Boutin, H, & Rothwell, N. J. in Pharmacology of Cerebral Ischaemia (eds Krieglstein, J. & Klumpp, S.) 183-190 (Medpharm, Stuttgart, 2002).
56. Strijbos, P. J. & Rothwell, N. J. Interleukin-1β attenuates excitatory amino acid-induced neurodegeneration in vitro: involvement of nerve growth factor. J. Neurosci. 15, 3468-3474 (1995).
57. Carlson, N. G. et al. Inflammatory cytokines IL-1α, IL-1β, IL-6, and TNF-α impart neuroprotection to an excitotoxin through distinct pathways. J. Immunol. 163, 3963-3968 (1999).
58. Viviani, B. et al. Interleukin-1β enhances NMDA receptor-mediated intracellular calcium increase through activation of the Src family of kinases. J. Neurosci. 23, 8692-8700 (2003).
59. Pringle, A. K., Niyadurupola, N., Johns, P., Anthony, D. C. & Iannotti, F. Interleukin-1β exacerbates hypoxia-induced neuronal damage, but attenuates toxicity produced by simulated ischaemia and excitotoxicity in rat organotypic hippocampal slice cultures. Neurosci. Lett. 305, 29-32 (2001).
60. Busto, R. et al. Small differences in intraischemic brain temperature critically determine the extent of ischemic neuronal injury. J. Cereb. Blood Flow Metab. 7, 729-738 (1987).
61. Azzimondi, G. et al. Fever in acute stroke worsens prognosis. A prospective study. Stroke 26, 2040-2043 (1995).
62. Monroy, M., Kuluz, J. W., He, D., Dietrich, W. D. & Schleien, C. L. Role of nitric oxide in the cerebrovascular and thermoregulatory response to interleukin-1β. Am. J. Physiol. Heart Circ. Physiol. 280, H1448-H1453 (2001).
63. Maher, C. O., Anderson, R. E., Martin, H. S., McClelland, R. L. & Meyer, F. B. Interleukin-1β and adverse effects on cerebral blood flow during long-term global hypoperfusion. J. Neurosurg. 99, 907-912 (2003).
64. Fassbender, K., Schmidt, R., Mossner, R., Daffertshofer, M. & Hennerici, M. Pattern of activation of the hypothalamic-pituitary-adrenal axis in acute stroke. Relation to acute confusional state, extent of brain damage, and clinical outcome. Stroke 25, 1105-1108 (1994).
65. Srinivasan, D., Yen, J. H., Joseph, D. J. & Friedman, W. Cell type-specific interleukin-1β signaling in the CNS. J. Neurosci. 24, 6482-6488 (2004).
66. Touzani, O. et al. Interleukin-1 influences ischemic brain damage in the mouse independently of the interleukin-1 type I receptor. J. Neurosci. 22, 38-43 (2002). The first report that IL-1β has effects in the CNS that are not mediated through binding IL-1R1, the classical IL-1 signalling receptor.
67. Basu, A. et al. Interleukin-1 and the interleukin-1 type 1 receptor are essential for the progressive neurodegeneration that ensues subsequent to a mild hypoxic/ischemic injury. J. Cereb. Blood Flow Metab. 25, 17-29 (2005).
68. Parker, L. C., Luheshi, G. N., Rothwell, N. J. & Pinteaux, E. IL-1β signalling in glial cells in wildtype and IL-1R1 deficient mice. Br. J. Pharmacol. 136, 312-320 (2002).
69. Allan, S. M. & Rothwell, N. J. Cytokines and acute neurodegeneration. Nature Rev. Neurosci. 2, 734-744 (2001).
70. Vezzani, A. et al. Interleukin-1β immunoreactivity and microglia are enhanced in the rat hippocampus by focal kainate application: functional evidence for enhancement of electrographic seizures. J. Neurosci. 19, 5054-5065 (1999).
71. Chen, Y. & Swanson, R. A. Astrocytes and brain injury. J. Cereb. Blood Flow Metab. 23, 137-149 (2003).
72. John, G. R., Lee, S. C., Song, X., Rivieccio, M. & Brosnan, C. F. IL-1-regulated responses in astrocytes: relevance to injury and recovery. Glia 49, 161-176 (2005).
73. Basu, A., Krady, J. K. & Levison, S. W. Interleukin-1: a master regulator of neuroinflammation. J. Neurosci. Res. 78, 151-156 (2004).
74. Aloisi, F. Immune function of microglia. Glia 36, 165-179 (2001).
75. Pinteaux, E., Parker, L. C., Rothwell, N. J. & Luheshi, G. N. Expression of interleukin-1 receptors and their role in interleukin-1 actions in murine microglial cells. J. Neurochem. 83, 754-763 (2002).
76. Vela, J. M., Molina-Holgado, E., Arevalo-Martin, A., Almazan, G. & Guaza, C. Interleukin-1 regulates proliferation and differentiation of oligodendrocyte progenitor cells. Mol. Cell. Neurosci. 20, 489-502 (2002).
77. Mason, J. L., Suzuki, K., Chaplin, D. D. & Matsushima, G. K. Interleukin-1β promotes repair of the CNS. J. Neurosci. 21, 7046-7052 (2001).
78. Konsman, J. P., Vigues, S., Mackerlova, L., Bristow, A. & Blomqvist, A. Rat brain vascular distribution of interleukin-1 type-1 receptor immunoreactivity: relationship to patterns of inducible cyclooxygenase expression by peripheral inflammatory stimuli. J. Comp. Neurol. 472, 113-129 (2004).
79. Proescholdt, M. G. et al. Intracerebroventricular but not intravenous interleukin-1β induces widespread vascular-mediated leukocyte infiltration and immune signal mRNA expression followed by brain-wide glial activation. Neuroscience 112, 731-749 (2002).
80. Bernardes-Silva, M., Anthony, D. C., Issekutz, A. C. & Perry, V. H. Recruitment of neutrophils across the blood-brain barrier: the role of E- and P-selectins. J. Cereb. Blood Flow Metab. 21, 1115-1124 (2001).
81. Anthony, D. et al. CXC chemokines generate age-related increases in neutrophil-mediated brain inflammation and blood-brain barrier breakdown. Curr. Biol. 8, 923-926 (1998).
82. Mazzotta, G. et al. Different cytokine levels in thrombolysis patients as predictors for clinical outcome. Eur. J. Neurol. 11, 377-381 (2004).
83. Fassbender, K. et al. Proinflammatory cytokines in serum of patients with acute cerebral ischemia: kinetics of secretion and relation to the extent of brain damage and outcome of disease. J. Neurol. Sci. 122, 135-139 (1994).
84. Tarkowski, E. et al. Early intrathecal production of interleukin-6 predicts the size of brain lesion in stroke. Stroke 26, 1393-1398 (1995). One of the earliest studies to show that concentrations of IL-1β are increased in patients who have suffered a clinical stroke.
85. Kostulas, N., Pelidou, S. H., Kivisakk, P., Kostulas, V. & Link, H. Increased IL-1β, IL-8, and IL-17 mRNA expression in blood mononuclear cells observed in a prospective ischemic stroke study. Stroke 30, 2174-2179 (1999).
86. Beamer, N. B., Coull, B. M., Clark, W. M., Hazel, J. S. & Silberger, J. R. Interleukin-6 and interleukin-1 receptor antagonist in acute stroke. Ann. Neurol. 37, 800-805 (1995).
87. Fassbender, K. et al. Inflammatory cytokines in subarachnoid haemorrhage: association with abnormal blood flow velocities in basal cerebral arteries. J. Neurol. Neurosurg. Psychiatry 70, 534-537 (2001).
88. Mathiesen, T., Edner, G., Ulfarsson, E. & Andersson, B. Cerebrospinal fluid interleukin-1 receptor antagonist and tumor necrosis factor-α following subarachnoid hemorrhage. J. Neurosurg. 87, 215-220 (1997).
89. Gladstone, D. J., Black, S. E. & Hakim, A. M. Toward wisdom from failure: lessons from neuroprotective stroke trials and new therapeutic directions. Stroke 33, 2123-2136 (2002).
90. Bresnihan, B. The safety and efficacy of interleukin-1 receptor antagonist in the treatment of rheumatoid arthritis. Semin. Arthritis Rheum. 30, 17-20 (2001).
91. Fisher, C. J. Jr. et al. Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial. The IL-1RA Sepsis Syndrome Study Group. Crit. Care Med. 22, 12-21 (1994).
92. Opal, S. M. et al. Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a Phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group. Crit. Care Med. 25, 1115-1124 (1997).
93. Stroke Therapy Academic Industry Roundtable II. Recommendations for clinical trial evaluation of acute stroke therapies. Stroke 32, 1598-1606 (2001).
94. Emsley, H. C. et al. A randomised Phase II study of interleukin-1 receptor antagonist in acute stroke patients. J. Neurol. Neurosurg. Psychiatry (in the press). The findings of the first clinical trial of IL-1RA for the treatment of patients who have suffered an acute stroke.
95. Springborg, J. B., Frederiksen, H. J., Eskesen, V. & Olsen, N. V. Trends in monitoring patients with aneurysmal subarachnoid haemorrhage. Br. J. Anaesth. 94, 259-270 (2005).
96. Campbell, S. J. et al. CINC-1 is an acute-phase protein induced by focal brain injury causing leukocyte mobilization and liver injury. FASEB J. 17, 1168-1170 (2003).
97. Obal, F. Jr. et al. Interleukin 1α and an interleukin 1β fragment are somnogenic. Am. J. Physiol. 259, R439-R446 (1990).
98. Fang, J., Wang, Y. & Krueger, J. M. Effects of interleukin-1β on sleep are mediated by the type I receptor. Am. J. Physiol. 274, R655-R660 (1998).
99. Avital, A. et al. Impaired interleukin-1 signaling is associated with deficits in hippocampal memory processes and neural plasticity. Hippocampus 13, 826-834 (2003).
100. Vamvakopoulos, J., Green, C. & Metcalfe, S. Genetic control of IL-1β bioactivity through differential regulation of the IL-1 receptor antagonist. Eur. J. Immunol. 32, 2988-2996 (2002).
101. Francis, S. E. et al. Interleukin-1 receptor antagonist gene polymorphism and coronary artery disease. Circulation 99, 861-866 (1999).
102. Worrall, B. B. et al. Interleukin-1 receptor antagonist gene polymorphisms in carotid atherosclerosis. Stroke 34, 790-793 (2003).
103. Dominici, R. et al. Cloning and functional analysis of the allelic polymorphism in the transcription regulatory region of interleukin-1α. Immunogenetics 54, 82-86 (2002).
104. Um, J. Y. et al. Association of interleukin-1α gene polymorphism with cerebral infarction. Brain Res. Mol. Brain Res. 115, 50-54 (2003).
105. Seripa, D. et al. Relevance of interleukin-1 receptor antagonist intron-2 polymorphism in ischemic stroke. Cerebrovasc. Dis. 15, 276-281 (2003).
106. Lee, B. C. et al. Susceptibility for ischemic stroke in Korean population is associated with polymorphisms of the interleukin-1 receptor antagonist and tumor necrosis factor-α genes, but not the interleukin-1β gene. Neurosci. Lett. 357, 33-36 (2004).
107. Iacoviello, L. et al. Polymorphisms of the interleukin-1β gene affect the risk of myocardial infarction and ischemic stroke at young age and the response of mononuclear cells to stimulation in vitro. Arterioscler. Thromb. Vasc. Biol. 25, 222-227 (2005).
108. Cullup, H., Middleton, P. G., Duggan, G., Conn, J. S. & Dickinson, A. M. Environmental factors and not genotype influence the plasma level of interleukin-1 receptor antagonist in normal individuals. Clin. Exp. Immunol. 137, 351-358 (2004).
109. Ooboshi, H., Ibayashi, S., Takada, J., Kumai, Y. & Iida, M. Brain ischemia as a potential target of gene therapy. Exp. Gerontol. 38, 183-187 (2003).
110. Spera, P. A., Ellison, J. A., Feuerstein, G. Z. & Barone, F. C. IL-10 reduces rat brain injury following focal stroke. Neurosci. Lett. 251, 189-192 (1998).
111. Molina-Holgado, F. et al. Endogenous interleukin-1 receptor antagonist mediates anti-inflammatory and neuroprotective actions of cannabinoids in neurons and glia. J. Neurosci. 23, 6470-6474 (2003).